Dose-Response · 2020 · 13 citations · 20 references
MedicineOncologyPharmacologyCancer ScreeningChemotherapyPharmacogeneticsGenetic Risk AssessmentGenotoxicity AssessmentGenotoxicity Risk AssessmentMolecular ScreeningToxicity PreventionToxicity Risk AssessmentCancer Screening StrategiesDihydropyrimidine Dehydrogenase TestingDpyd Fluoropyrimidine ToxicityDpyd GenotypeDpyd GenotypingDrug Toxicity DetectionDrug Toxicity RiskToxicity Screening Assays
Background: Fluoropyrimidines (FPs) carry around 20% risk of G3-5 toxicity and 0.2-1% risk of death, due to dihydropyrimidine dehydrogenase (DPD) deficiency. Several screening approaches exist for predicting toxicity, however there is ongoing debate over which method is best. This study compares 4 screening approaches. Method: 472 patients treated for colorectal, head-and-neck, breast, or pancreatic cancers, who had not been tested pre-treatment for FP toxicity risk, were screened using: DPYD genotyping (G); phenotyping via plasma Uracil (U); phenotyping via plasma-dihydrouracil/uracil ratio (UH 2 /U); and a Multi-Parametric Method (MPM) using genotype, phenotype, and epigenetic data. Performance was compared, particularly the inability to detect at-risk patients (false negatives). Results: False negative rates for detecting G5 toxicity risk were 51.2%, 19.5%, 9.8% and 2.4%, for G, U, UH 2 /U and MPM, respectively. False negative rates for detecting G4-5 toxicity risk were 59.8%, 36.1%, 21.3% and 4.7%, respectively. MPM demonstrated significantly (p < 0.001) better prediction performance. Conclusion: MPM is the most effective method for limiting G4-5 toxicity. Its systematic implementation is cost-effective and significantly improves the risk-benefit ratio of FP-treatment. The use of MPM, rather than G or U testing, would avoid nearly 8,000 FP-related deaths per year globally (500 in France), and spare hundreds of thousands from G4 toxicity.
20
Systemic Therapy for Colorectal Cancer
Jeffrey A. Meyerhardt, Robert J. Mayer · New England Journal of Medicine · 2005 · 1.1K citations
Medicine, Oncology, Pharmacology +17
Systemic Therapy for Colorectal Cancer
Anna M. Varghese · DeckerMed CGSO Case-Based Reviews · 2019 · 883 citations
Medicine, Oncology, Pharmacology +17
Robert B. Diasio, T L Beavers, John T. Carpenter · Journal of Clinical Investigation · 1988 · 500 citations · Full text
Medicine, Biochemistry, Pharmacology +14